

Post Streptococcal Syndromes, A Rheumatologist Perspective

D Ivory, D Folzenlogen

Citation

D Ivory, D Folzenlogen. *Post Streptococcal Syndromes, A Rheumatologist Perspective*. The Internet Journal of Rheumatology. 2009 Volume 6 Number 2.

Abstract

Post streptococcal syndromes may manifest in multiple organs including the musculoskeletal, central nervous, urinary, integumentary, and circulatory systems. The commonly described post streptococcal syndromes include acute rheumatic fever, post streptococcal glomerulonephritis, post streptococcal arthritis, and pediatric autoimmune neuropsychiatric disorders. Classically, these complications occur more often in children. While much is written in the pediatric literature regarding these syndromes, a compilation of information is difficult to find. This article summarizes some of the frequently described post streptococcal syndromes and associations.

DESCRIPTION OF STREPTOCOCCUS

Group A beta-hemolytic streptococci (GAS), *Streptococcus pyogenes*, the most extensively studied member of the streptococcal family is a gram-positive cocci that appears in chains and pairs and demonstrates beta hemolysis (full lysis) on blood agar. Five to fifteen percent of the general population harbor this bacterium in the upper respiratory tract without disease.¹ Nonetheless, GAS maybe responsible for numerous infections and infection related syndromes.(Table 1).¹⁻⁴

Figure 1

Table 1	
Complications of Group A beta-hemolytic Streptococcal Infections	
Nonsuppurative	
<i>Rheumatic fever</i>	
<i>Post streptococcal glomerulonephritis</i>	
<i>Rheumatic heart disease</i>	
<i>Sydenham's chorea</i>	
<i>Post streptococcal reactive arthritis</i>	
<i>Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS)</i>	
Suppurative	
<i>Erysipelas</i>	
<i>Invasive cellulitis</i>	
<i>Impetigo</i>	
<i>Endocarditis</i>	
<i>Myositis/ Necrotizing fasciitis</i>	
<i>Meningitis</i>	
<i>Perianal dermatitis of children</i>	
<i>Otitis media</i>	
<i>Toxic shock</i>	
<i>Bacteremia</i>	
<i>Mastoiditis</i>	
<i>Cervical adenitis</i>	
<i>Pneumonia</i>	
<i>Newborn sepsis (puerperal fever)</i>	
<i>Scarlet fever</i>	
<i>Pharyngitis</i>	
<i>Peritonsillar or retropharyngeal abscess</i>	

PATHOPHYSIOLOGY

Streptococcus is classified based on antigen serology (Lancefield groups) to certain polysaccharides in the bacterium cell wall. GAS has an extensive array of virulent factors (Table 2).^{1,5,6} M proteins, virulent factors found on the cell surface oppose phagocytosis. Over 50 antigenically distinct M proteins are associated with GAS.¹ M proteins often divide into rheumatogenic and nephritogenic

serotypes. Serotypes 5, 6, and 19 relate to human heart tissue and serotypes of 1, 12, and 49 relate to renal tissue.^{7,8} Some serotypes are associated with both arthritis and renal syndromes.

Figure 2

<i>M</i> proteins and the hyaluronic acid capsule	Inhibits phagocytosis
Invasins: Streptokinins	Promote spread
Invasins: Streptodornase (anti DNase B)	Promote spread
Invasins: Streptolysin	Promote spread
Invasins: Hyaluronase	Promote spread
Exotoxins (pyogenic toxins)	Act directly or as superantigens
Protein F (fibronectin binding protein)	Promote adherence
Lipoteichoic acid	Promote adherence
C5a peptidase	Inhibit neutrophil migration
Streptococcal chemokine protease	Inhibit neutrophil migration

EPIDEMIOLOGY

The global burden of severe GAS disease is estimated to be greater than 500,000 deaths a year, primarily from rheumatic heart disease. The estimated prevalence of severe GAS disease (e.g., acute rheumatic fever, rheumatic heart disease, post-streptococcal glomerulonephritis, and invasive infections) is 18 million cases.⁹ Superficial GAS diseases such as pyoderma and pharyngitis also contribute to disease burden. Some countries in Indio Pacific and Middle Eastern regions report symptomatic pharyngitis 5-10 times that of other more developed countries.⁹

In the United States, approximately 8,950-11,500 cases of invasive GAS disease occur each year, with 1,050-1,850 deaths.¹⁰ Toxic shock syndrome and necrotizing fasciitis each represent about 6%-7% of these cases.¹¹ However, several million cases of strep throat and impetigo are reported each year.¹¹

IMMUNE MEDIATED THEORY

The suspected relationship of streptococcal disease and post-streptococcal immune mediated sequelae is expanding, but making such an association between an infection and a post infectious syndrome requires certain criteria (Table 3).¹² Several immune mechanisms may be operable in post streptococcal syndromes such as antibody directed molecular mimicry in rheumatic fever,^{13,14} and possible super antigen stimulation of T cells in Kawasaki disease and guttate psoriasis.^{15,16}

Figure 3

1. Temporal relationship to infection
2. Animal model in which infection precipitates the autoimmune/inflammatory manifestations
3. Identifying the responsible microbial antigen/protein and self protein epitopes that are relevant or cross reactive
4. Documenting T cells that cross react to microbial and self epitopes

EVALUATION FOR STREPTOCOCCUS

Antistreptolysin O (ASO) and anti DNase B antibodies are the most consistently studied streptococcal antibodies. Prior data suggested that individually, anti DNase B or ASO have 70% sensitivity 86-93% and specificity. The combined elevation of both (ASO and anti DNase B) revealed a sensitivity of 95% and specificity of 98%.¹⁷ A more recent study reports single point antibody titers are unreliable and GAS infection assessment may require a correlation with increasing antibody titers.¹⁸

Post streptococcal syndromes usually occur 1-3 weeks after pharyngitis or skin infection. Some syndromes may occur within a few days of infection, making antibody confirmation of disease difficult. Therefore reexamining titers after several weeks is important. Other syndromes (movement and neuropsychological) may be occult and occur months after the inciting infection.

POST STREPTOCOCCAL SYNDROMES

ACUTE RHEUMATIC FEVER (ARF)

OVERVIEW

Rheumatic fever is a multisystem nonsuppurative complication of GAS infections. Most patients present several weeks after streptococcal pharyngitis or scarlet fever,² but in others no identifiable infection is found. Over twenty million children world wide experience rheumatic fever and up to 4% relate to untreated streptococcal infections.¹⁹ In the United States outbreaks of ARF have steadily declined over the past 80 years and the disease is relatively uncommon. Most outbreaks occur in developing countries in areas plagued by impoverished overcrowded conditions with limited access to antibiotic therapy. The worldwide estimates of ARF are up to 471,000 cases per year, with the highest rates in aboriginal populations and New Zealand.⁹

CLINICAL FEATURES

Migratory polyarthralgia or arthritis generally involves the lower joints but can migrate to the upper extremities.² This occurs early in the disease often the earliest complaint. Up to

17% of patients present with a mono-arthritis usually involving the knee.²⁰ Small pea size painless subcutaneous nodules of extensor surfaces are seen in less than 10% of patients.²¹ This is frequently seen in association with carditis.²² Carditis may manifest as pericarditis, myocarditis or endocarditis.^{22,21} The mitral valve is almost always affected although any valve can be involved. Mitral stenosis and calcification are common manifestations of long standing rheumatic heart disease.² Rheumatic heart disease post ARF may be as high as 60%.^{9,23} Erythema marginatum, primarily involves the trunk, consisting of evanescent erythematous rings that spares the face.²² Sydenhams chorea is a late manifestation (discussed in more detail later), and typically occurs weeks to months after the streptococcal infection.

DIAGNOSIS

The Jones criteria (Table 4), was established to make a presumptive diagnosis of ARF.²⁴ Two major, or one major and two minor criteria, along with evidence of recent or current streptococcal infection as documented by throat culture, increasing ASO or anti DNase B, are considered sufficient to make the diagnosis.

Figure 4
Table4

Table 4	
<i>The Jones Criteria for ARF</i>	
Major criteria	
Migratory polyarthritis	
Subcutaneous nodules	
Sydenham's chorea	
Carditis	
Erythema marginatum	
Minor criteria	
Fever	
Arthralgias	
Leukocytosis	
Elevated or rising Antistreptolysin O titer or DNase	
Raised Erythrocyte sedimentation rate or C reactive protein	
Prior episode of rheumatic fever or inactive heart disease	
ECG changes showing heart block or prolonged PR interval	

IMMUNOPATHOLOGY

The most compelling etiopathogenic theory in rheumatic fever and heart disease suggests antibodies to N-acetyl glucosamine of the streptococcus demonstrate cross reactivity with human laminin and myosin.^{22,25} These antibodies may also contribute to the infiltration of T cells, triggering the release of cytokines contributing to inflammation and granuloma formation (aschoff bodies) of the sub endocardium leading to valve scarring. Genetic links including HLA-DRB1*07 and HLA-DR*16 have been reported with ARF and rheumatic heart disease.^{26,27}

TREATMENT

Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) for arthritis and appropriate antibiotics therapy {penicillin or erythromycin for penicillin allergy}.²² A recent streptococcal pharyngitis meta-analysis has shown that the cephalosporin cure rate may be superior to

penicillin.²⁸ Antibiotic prophylaxis is suggested for patients with persistent valvular heart disease for at least 10 years after the last episode of acute rheumatic fever or until 40 years of age, whichever is longer.²⁹ In patients without persistent valvular disease, prophylaxis is recommended to continue for 10 years or until the patient is 21 years of age, whichever is longer.²⁹ Post streptococcal arthritis (PSRA)

OVERVIEW

Post streptococcus reactive arthritis is an acute nonsuppurative arthritis following a known streptococcal infection. It was first described in 1959 by Crea and Mortimer as “Scarlatinal arthritis”, later described by Goldsmith et al in children who failed to meet criteria for ARF.³⁰⁻³² Classically, this follows pharyngitis by 3-14 days. Over 80% of PSRA are GAS affiliated, but it can be seen with group B, C, and G infections, as well.^{30,33,34} Peak incidence is often bimodal, in ages 8-14 years and 21-37 years.³³

CLINICAL FEATURES

Proposed criteria for the diagnosis includes evidence of prior strep infection, a non migratory arthritis, recurrent or protracted arthritis and arthritis not highly responsive to NSAIDs.³⁵ It can manifest in any joint including axial joints in 24% of cases.²⁷

DIAGNOSIS/TREATMENT

PSRA is treated with NSAIDs tapered off as the arthritis improves.³⁰ Patients may require several months of treatment. All patients should be treated for streptococcus infection as well. Because of the quick onset of arthritis, the initial ASO and anti DNase B titers may not be elevated. Titers should be repeated a few weeks post infection. Some consider PSRA a variant of ARF supported by the finding that about 6% of patients have silent carditis found on echocardiograms usually 6 months after the onset of arthritis.^{27,30} The American Heart Association suggest antibiotic prophylaxis for at least one year, and if carditis is not observed prophylaxis can then be discontinued.³⁶

POST STREPTOCOCCAL RELATED MYALGIA/MYOSITIS

Myalgias are reported in association with streptococcal and/or post streptococcal syndromes. Clinical presentations include severe muscle pain and/or tenderness.^{37,38} Laboratory data may show elevation in sedimentation rates and leukocytosis, but muscle enzymes and muscle biopsies may be normal. Several cases of post streptococcal polymyalgias

have responded to penicillin, NSAIDs or steroid therapy.³⁸⁻⁴⁰ Orbital myositis has been reported to respond to antibiotic and anti-inflammatory therapies.⁴¹⁻⁴³

POST STREPTOCOCCAL GLOMERULONEPHRITIS (PSGN)

OVERVIEW

PSGN is nephritis with or without oliguric renal failure, and occurs one to three weeks after pharyngitis or skin disease. An estimated 470,000 cases of PSGN occur per year accounting for 5000 deaths annually.⁹ The majority of deaths occur in developing countries.

CLINICAL FEATURES

Patients can present with peri-orbital edema, hematuria (tea, dark, coke colored urine), hypertension, malaise, weakness and back pain. Children may have a mild subclinical course.

IMMUNOPATHOLOGY MECHANISM

The immune mechanisms for PSGN are unclear, but immune complex disease, is likely. IgG and C3 immune deposits are present in the mesangial basement membrane with increased cellularity and evidence of endothelium proliferation. Other proposed mechanisms include cross reactive antibodies and exotoxins. SpeB (Strep exotoxins B) has been identified in biopsies, but its role is unclear.^{44,45} Nordstrad et al has speculated SpeB may induce massive cytokine production and by cleavage mechanisms cause the release of M proteins, C5a peptidase and other surface bound streptococcal antigens.^{46,47,44} Some of the nephritogenic M type products may inhibit complement function, including SIC (Streptococcal inhibitor of complement), CRS (Closely related to SIC) and DRS (Distantly related to SIC).^{48,49,50}

DIAGNOSIS/TREATMENT

Most patients have mild, non-progressive disease and are not biopsied. Typically a low serum C3 and mild renal insufficiency are seen. Occasionally progression to chronic renal failure occurs. Ongoing streptococcal infections should be treated. However, most patients are treated supportively.

POST STREPTOCOCCAL CNS SYNDROMES OVERVIEW

Post streptococcal CNS syndromes are difficult to categorize. Syndromes may overlap and the symptoms may be remote from the inciting infection. The following syndromes or manifestation have been reported or proposed.

SYNDEHAMS CHOREA (SC)

SC was first described in the 17th century although its association with streptococci and rheumatic fever was not noted until the late 1800's. Not until 1950 was the association made with GAS. SC usually manifests weeks to months after a streptococcal infection, although occasionally within one week. Typically, chorea is bilateral, uncontrolled purposeless, rapid movement of the limbs with associated emotional lability.⁵⁰ Chorea is a major criterion of ARF and thought to be a result of cross reactive antibodies to brain tissue.⁵¹⁻⁵³ T and B cells may participate in CNS surveillance under "normal conditions," and these lymphocytes potentially recognize self antigens, release cytokines and chemokines, and recruit more inflammatory cells. This may suggest a loss of tolerance of auto reactive T and B cells perhaps due to streptococcal antigen.^{50,55,56}

Most episodes are monophasic, but up to 42% relapse.⁵⁰ These relapses may be related to streptococci or other infectious triggers.⁵⁰ SC manifestations are variable lasting for several months to years. Tics, attention deficit hyperactive disorder (ADHD), depression and obsessive-compulsive disorder (OCD) have been described in association with syndehams chorea.^{54,55} In one report a family history of rheumatic fever and/or SC was seen in up to 36% of patients.⁵⁰

PANDAS

Pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) is a group of neurological sequelae that includes chorea, tics, obsessive compulsive behavior, ADHD, depression, anxiety and oppositional defiant behaviors (ODB). Making a temporal relationship of PANDAS with streptococcal infection has been controversial. Some studies have demonstrated patients with PANDAS have increased serum levels of antineuronal antibodies.⁵⁶⁻⁵⁸ The proposed criterion for PANDAS is inexact and non-discriminating (Table 5).^{59,60} Two clinically distinct phenotypes have been defined; movement disorders (Tics, chorea and dystonia) and psychiatric disorder (OCD, ADHD, anxiety, depression and oppositional defiant behaviors). An additional classification scheme suggests central nervous hyperkinetic syndromes (movement, insomnia and anxiety) or hypo-kinetic syndromes (depression and hyper-somnolence).⁵⁰

Figure 5

Table 5 Proposed criteria for PANDAS	
1.	OCD or tics
2.	Pre-puberty onset
3.	Episode is abrupt
4.	Associated with group A streptococci
5.	Associated with neuron abnormalities and adventitious movements ADHD or chorea.

Swedo et al in 1998

MOVEMENT DISORDERS ASSOCIATED WITH PANDAS

1. TICS

Tics are sudden, repetitive, stereotyped motor movements or phonic productions.⁶¹ The concept of post-streptococcal tics was first described in 1980 with an outbreak of tonsillitis in Rhode Island when there was a 10 fold increase in cases of tics.⁵⁷ Tics may recur or worsen with recurrent streptococcal infections.⁶⁰

2. MYOCLONUS AND DYSTONIA

Myoclonus is brief involuntary muscle twitching and dystonia is sustained muscle contractions with twisting, repetitive movements or abnormal postures. Myoclonus and dystonia have been associated with post streptococcal disease and both have been described with and without Parkinson features.^{62,63} Occasionally a Parkinson phenotype is associated with hyperkinetic and/or hypo kinetic syndromes.^{50,64,63}

3. SYNDEHAMS CHOREA-SEE PRIOR DISCUSSION.

BEHAVIORAL/PsYCHIATRIC DISORDERS ASSOCIATED WITH PANDAS

OCD AND ADHD

Psychiatric and behavioral manifestations are common.^{60,65,66,63} Streptococcal infections may precede OCD symptoms by months.⁶⁰ There is some suggestion that ADHD may predate the development of post streptococcal movement disorders.⁶³

ENCEPHALITIS LETHARGICA (EL)

EL was first described in the early 1900's (perhaps the precursor for the PANDAS syndrome) with symptoms of headache, malaise, fatigue, insomnia and ophthalmologic manifestations.⁶⁷ EL has associated insidious movement and/or psychiatric disorders including Parkinson's, oculogyric crisis, chorea, myoclonus, mutism, catatonia, and behavioral problems such as anxiety, depression, and

OCD.^{64,67} EL can occur in a wide age range from 2-69, most cases reported in children or teenagers.⁶⁴ Dale and colleagues described CSF findings of elevated protein and oligoclonal bands in EL patients.⁶⁴ Magnetic resonance imaging (MRI) demonstrated inflammatory changes on T2 weighted images in 40% of these patients.⁶⁷ Sixty-five percent of these patients also had elevated ASO titers.⁶⁷

CNS VASCULITIS

CNS vasculitis has been reported in conjunction with PSGN.⁶⁸⁻⁷⁰ One case report described vasogenic edematous changes on MRI imaging and Doppler stenosis of both extra and intra cranial vessels. CNS vasculitis patients generally presented with seizures and cognitive dysfunction. Most improve with steroid treatment.^{71,68,69}

DIAGNOSIS CNS SYNDROMES

Assessing for anti-neuronal antibodies in the CSF and serum has produced inconsistent results between different antineuronal assays.⁵⁰ Currently, it is not routinely recommended to test for anti-neuronal antibodies in the clinical setting.⁵⁰

Most post streptococcal CNS syndromes have normal neuroimaging. However, nonspecific MRI abnormalities are reported in some.^{50,63}

TREATMENT CNS SYNDROMES

Antibiotics for infection and prophylaxis are important especially if there is evidence of syndehams chorea or rheumatic fever.⁷² A prospective study suggested antibiotic treatment of tonsillitis showed improvement in OCD manifestations.⁷³ A double blinded randomized control trial suggested a reduction in the incidence of post streptococcal CNS manifestations with the use of prophylactic antibiotics.⁷⁴ In a review article by Dale, he cited several articles that suggested that PANDAS syndromes may respond to steroids, plasma exchange, IVIG, however, no current recommendations for treatment with these agents is has been suggested at this time.⁵⁰

POST STREPTOCOCCAL SYSTEMIC VASCULITIS

HENOCH-SCHÖNLEIN PURPURA (HSP)

Henoch-Schönlein purpura is an IgA mediated small vessel vasculitis and is the most common vasculitis in children. The incidence is approximately 10- 20/100,000.⁷⁵⁻⁷⁷ HSP is usually preceded by an upper respiratory infection (including streptococcal infections) and may manifest with palpable

purpura, arthralgia/arthritis, abdominal pain (due to vasculitis and intussusception in some), or renal disease.^{78,82-84} Renal findings include hematuria and proteinuria associated with mesangial involvement. Incomplete HSP presentations occur.

Patients with streptococcal associated HSP may have a low C3 and elevated ASO titers.⁷⁶ One case control study reported elevated ASO titers associated with a tenfold increase risk for HSP compared to patients with negative titers.⁷⁹ Nephritis-associated plasmin receptor (NAPlr), a GAS antigen, has been reported in glomerular biopsies of patients.⁸⁰ Renal disease is usually limited and the prognosis is good, although occasionally patients develop progressive renal failure with nephrotic syndrome.^{81,76} Treatment for progressive renal disease includes steroids and cytotoxic agents.⁷⁵ Renal disease, if associated with streptococci, may respond to antibiotics.⁸²

The arthritis associated with HSP; primarily involves the lower extremity large joints. It often responds to NSAID therapy.

POLYARTERITIS NODOSA (PAN)

Polyarteritis nodosa is a small and medium vessel vasculitis, usually seen in middle age men. In children it tends to be a disease of pre-teen males. It can occur in the systemic form with multiple organ involvement or in the cutaneous form (discussed later). Symptoms include constitutional manifestations, muscle pain, arthritis, abdominal discomfort and abnormal urinalysis. While cutaneous PAN has been associated with streptococci, only a few cases of the systemic form have been reported post streptococcal.⁸³

KAWASAKI'S DISEASE (KD)

Kawasaki's disease a multisystem medium vasculitis commonly affecting children is characterized by prolonged fever, conjunctivitis, erythema (especially of the extremities and trunk), inflamed oral mucosa, cracked lips, strawberry tongue, desquamating rash of distal extremities (fingers and toes), and cervical adenopathy.⁸⁴

Streptococcal and staphylococcal superantigens and/or infections have been suspected in the pathology.⁸⁵⁻⁹¹ Over the past three decades a single microbial cause has not consistently been identified.^{84,92} Several theories postulate the connection of KD and streptococcal infections, these include streptococcal antigen as an inciting factor causing clonal T cell expansion and may stimulate T cells with specific TCR V [beta] types.⁹³⁻⁹⁵ Researchers have suggested

staphylococcal enterotoxin A (SEA), SEB, SEC, toxic shock syndrome toxin-1 (TSST-1), and streptococcal pyrogenic exotoxin A (SPEA) may be involved in the pathogenesis based on documented elevations of IgM antibodies to these antigens in KD patients.⁸⁶

The initial treatment of KD may include antibiotics because of a suspected bacterial infection, but the standard treatment of KD includes IVIG and aspirin in the early acute febrile phase.⁸⁴ Re-treatment may be indicated if the patient is no better within 36 hours of the initial IVIG infusion.^{84,92} In refractory cases of KD, some have considered steroids, plasma exchange, cyclosporine and possibly biologics; however, lack of controlled data makes treatment recommendations with these agents unclear.⁸⁴

POST STREPTOCOCCAL DERMATOLOGIC MANIFESTATIONS

Overview

Infection and colonization's of skin with bacteria may lead to inflammatory skin disease. Toxins from streptococcal and staphylococcal may act as allergic superantigens.

CUTANEOUS POLYARTERITIS NODOSA (CPAN)

CPAN is a pan arteritis of the subcutaneous and deep dermal arterioles, post capillary venules, without systemic involvement.⁹⁶ Painful small (0.5- 2 cm in diameter) nodules that may ulcerate are typical. Patients may have elevated sedimentation rates, fever, arthralgias, myalgias, leukocytosis or leukopenia. The etiology is unknown. Fibrinoid degeneration of the elastic lamina of small and medium vessels with findings of fibrin, C3 and IgM deposits are seen on excisional biopsies of skin nodules.⁹⁷ An association with viral hepatitis infections is described in the literature and there are reports of post streptococcal infection association.^{83,98-104} A small retrospective review, positive ASO titers or throat cultures in up to seventy-five percent of patients.¹⁰³

CPAN may relapse with recurrent streptococcal infections. In these cases long term treatment with antibiotics may be necessary,¹¹⁰ in some immunosuppression may be required.^{99,101,104} A case report of a 13 year old presenting with polyarthrititis, myalgias, elevated ASO titers and biopsy findings of necrotizing vasculitis, showed improvement with prednisone and penicillin.¹⁰⁵ Disease recurrences was noted with penicillin withdrawal.¹⁰⁵ Another case report implicated dental carries and abscesses as a source of streptococcal

related CPAN. Extraction of teeth and abscess drainage resolved the vasculitis.¹⁰⁶

PUSTULAR VASCULITIS (PV)

PV is generally classified as a neutrophilic dermatosis. It was first described by Strutten et al in 1995.¹⁰⁷ Large purple purpuric based blisters and pustules on the dorsum of the hands, laterally between digits (especially between the thumb and index) and on the soles of the feet are classic.¹⁰⁷ PV is usually treated with prednisone. An association with streptococcus, including elevations of ASO, has been reported.¹⁰⁸ In such patients antibiotic treatment may be indicated.¹⁰⁸

ERYTHEMA ELEVATUM DIUTINUM (EED)

EED are red edematous purpuric plaques on the extensor surfaces of the body. A leukocytoclastic vasculitis with fibrinoid necrosis is the primary histopathology.¹⁰⁹ An allergic reaction to streptococcal superantigens as suggested in one case report.¹¹⁰ Dapsone is usually the treatment of choice.^{111,109,110}

POST STREPTOCOCCAL PUSTULOSIS (PAG)

PAG is a rare condition manifesting as small pustules on normal skin in the acral location.¹¹² It is associated with fever, arthropathy, leukocytosis, elevated sedimentation rates and in some, elevated ASO titers. The histological findings include sub corneal spongiform pustules within normal epidermis and progression to leukocytoclastic vasculitis.¹¹³ PAG may occur in the first few weeks after streptococcal infection. It is commonly treated with antibiotics and steroids.^{114,112,113}

PANNICULITIS AND ERYTHEMA NODOSA (EN)

Panniculitis is a group of disorders characterized by inflammation of subcutaneous adipose tissue.¹¹⁵ EN, a subtype of panniculitis, (septal panniculitis) is considered the most common form of panniculitis seen in children.¹¹⁶ Raised painful subcutaneous erythematous nodules on the lower extremities, buttock and dependent areas are typical. Fatigue, weight loss, joint pain, infections, drugs, chronic inflammatory disease and malignancy may be associated.¹¹⁷

Streptococcal infection is the most common identifiable cause in children.^{115,117} However, the peak age of onset is 20-30, with females outnumbering males.¹¹⁷ In most patients, a prodrome of upper respiratory infection and/or evidence of a prior streptococcal pharyngitis are seen.¹¹⁷ Because, EN occur 2-3 weeks after streptococcal infections, obtaining

throat cultures, ASO and Anti DNase B titers at presentation is important. Pathological evidence suggests that EN is related to type IV hypersensitive reaction to a variety of antigens.¹¹⁷ Septal inflammation with neutrophilic infiltrate around proliferating capillaries with occasional hemorrhage, and small well defined nodular aggregates of histiocytes around a central stellate is seen.^{118,117} Lesions may take weeks to months to resolve. Along with treating the underlying triggers; NSAIDs and occasionally steroids may be required. For those with associated streptococcal infections treatment should include antibiotics.¹¹⁷

PSORIASIS

Psoriatic lesions are red, raised, often scaly and found primarily on the extensor surfaces, scalp, trunk and the periumbilical area. Reports have described streptococcal microbial products affecting the lesional epidermis of psoriasis patients.¹¹⁹ Streptococcal M proteins and skin keratins share some homology suggesting a pathologic role for cross reactivity.¹²⁰ A recent prospective trial of 248 patients revealed patients with chronic psoriasis reported sore throats ten times more often than controls.¹²¹ GAS was isolated in 10% of patients and only 1% of control.¹²⁷

GUTTATE PSORIASIS (GP)

Guttate psoriasis is characterized by sudden onset of diffuse red scaly papules that often resolve spontaneously but at times progress to chronic plaque psoriasis.¹²² The etiology is unknown. Genetic and environmental factors and possibly GAS may be involved.^{123,124,122} The onset occurs 1-2 weeks after an episode of tonsillitis or pharyngitis.¹²⁸ Studies demonstrating streptococci isolation from the throats of GP patients have shown that some isolates have the ability to produce streptococcal pyrogenic exotoxin C (SPEC) and superantigens known to stimulate certain V beta T cells regions.¹²⁵ Some have suggested that streptococcal infections may induce GP through superantigen driven generation of V beta-restricted (cutaneous lymphocyte associated antigen) CLA-positive skin homing lymphocytes.¹⁶

CHRONIC PLAQUE PSORIASIS (CPP)

CPP is the most common form of psoriasis characterized by erythematous plaques with silvery scales. The association of GAS, chronic psoriasis or psoriasis vulgaris remains largely anecdotal.¹²¹ There are reports of exacerbations of psoriasis in patients with tonsillitis and reports of significant remission rates after tonsillectomy and/or antibiotic treatment.¹²⁶⁻¹²⁹ A recent meta analysis did not show benefits in treating chronic psoriasis or guttate psoriasis with

antibiotics or tonsillectomy.¹²² Currently no specific recommendations can be made regarding these treatments.¹³⁰

CONCLUSION

In summary, post streptococcal syndromes and associations are often multi system. Clinicians should remember that most post streptococcal syndromes occur weeks to months after the initial infection. Searching for a previous history or evidence of streptococcal infection is important. Multisystem manifestations often suggest autoimmune diseases but the differential should include streptococcal related syndromes.

References

1. Todar K, University of Wisconsin, Department of Bacteriology. Streptococcus pyogenes and Streptococcal Disease. 2008. Available at: <http://www.textbookofbacteriology.net/streptococcus.html>.
2. Hahn RG, Knox LM, Forman TA. Evaluation of poststreptococcal illness. *Am Fam Physician*. 2005;71(10):1949-54.
3. Martin JM, Green M. Group A streptococcus. *Semin Pediatr Infect Dis*. 2006;17(3):140-8.
4. Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. *J Paediatr Child Health*. 2007;43(4):203-13.
5. Hidalgo-Grass C, Mishalian I, Dan-Goor M, et al. A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. *EMBO J*. 2006;25(19):4628-4637.
6. Ji Y, McLandsborough L, Kondagunta A, Cleary P. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. *Infect. Immun*. 1996;64(2):503-510.
7. Coovadia HM. Rheumatic fever and disorders of the musculoskeletal system. *Curr Opin Rheumatol*. 1992;4(5):718-24.
8. Khandke KM, Fairwell T, Manjula BN. Difference in the structural features of streptococcal M proteins from nephritogenic and rheumatogenic serotypes. *J Exp Med*. 1987;166(1):151-62.
9. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. *Lancet Infect Dis*. 2005;5(11):685-94.
10. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. *Clin Infect Dis*. 2007;45(7):853-62.
11. Disease Listing, Group A Streptococcal, General Info | CDC Bacterial, Mycotic Diseases. Available at: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_g.htm [Accessed June 27, 2010].
12. Samarkos M, Vaiopoulos G. The role of infections in the pathogenesis of autoimmune diseases. *Curr Drug Targets Inflamm Allergy*. 2005;4(1):99-103.
13. Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of Autoimmune Valvular Heart Disease by Recombinant Streptococcal M Protein. *Infect. Immun*. 2001;69(6):4072-4078.
14. Martins TB, Veasy LG, Hill HR. Antibody responses to group A streptococcal infections in acute rheumatic fever. *Pediatr Infect Dis J*. 2006;25(9):832-7.
15. Proft T, Fraser JD. Streptococcal superantigens. *Chem*

- Immunol Allergy. 2007;93:1-23.
16. Davison SC, Allen MH, Mallon E, Barker JN. Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. *Br J Dermatol*. 2001;145(2):245-51.
17. Blyth CC, Robertson PW. Anti-streptococcal antibodies in the diagnosis of acute and post-streptococcal disease: streptokinase versus streptolysin O and deoxyribonuclease B. *Pathology*. 2006;38(2):152-6.
18. Johnson DR, Kurlan R, Leckman J, Kaplan EL. The Human Immune Response to Streptococcal Extracellular Antigens: Clinical, Diagnostic, and Potential Pathogenetic Implications. *Clinical Infectious Diseases*. 2010;50(4):481-490.
19. Guilherme L, Fae KC, Higa F, et al. Towards a vaccine against rheumatic fever. *Clin Dev Immunol*. 2006;13(2-4):125-32.
20. Carapetis JR, Currie BJ. Rheumatic fever in a high incidence population: the importance of monoarthritis and low grade fever. *Arch Dis Child*. 2001;85(3):223-7.
21. EL. K. Rheumatic fever. New York: McGraw-Hill; 2005.
22. Carapetis JR. "Chapter 315. Acute Rheumatic Fever" (Chapter). Available at: <http://www.accessmedicine.com/content.aspx?aID=2881861>
23. Carapetis JR, Currie BJ, Mathews JD. Cumulative Incidence of Rheumatic Fever in an Endemic Region: A Guide to the Susceptibility of the Population? *Epidemiology and Infection*. 2000;124(2):239-244.
24. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. *JAMA*. 1992;268(15):2069-73.
25. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. *Front Biosci*. 2003;8:s533-43.
26. Haydardeed011Flu FE, Tutkak H, Köse K, Düzgün N. Genetic susceptibility to rheumatic heart disease and streptococcal pharyngitis: association with HLA-DR alleles. *Tissue Antigens*. 2006;68(4):293-296.
27. Ahmed S, Ayoub EM, Scornik JC, Wang CY, She JX. Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles. *Arthritis Rheum*. 1998;41(6):1096-102.
28. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. *Clin Infect Dis*. 2004;38(11):1526-34.
29. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation*. 2009;119(11):1541-51.
30. Ahmed S, Ayoub EM. Poststreptococcal Reactive Arthritis. *The Pediatric Infectious Disease Journal*. 2001;20(11):1081-1082.
31. Crea MA, Mortimer EA. THE NATURE OF SCARLATINAL ARTHRITIS. *Pediatrics*. 1959;23(5):879-884.
32. Goldsmith D, Long S. Poststreptococcal disease of childhood—a changing syndrome. *Arthritis Rheum*. 1982;S18(25:S18).
33. Mackie SL, Keat A. Poststreptococcal reactive arthritis: what is it and how do we know? *Rheumatology (Oxford)*. 2004;43(8):949-54.
34. Woo PC, Teng JL, Lau SK, et al. Analysis of a viridans group strain reveals a case of bacteremia due to lancefield group G alpha-hemolytic *Streptococcus dysgalactiae* subsp *equisimilis* in a patient with pyomyositis and reactive arthritis. *J Clin Microbiol*. 2003;41(2):613-8.
35. Ayoub EM, Majeed HA. Poststreptococcal reactive arthritis. *Curr Opin Rheumatol*. 2000;12(4):306-10.
36. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. *Pediatrics*. 1995;96(4 Pt 1):758-64.
37. GREMSE DA, WALTERSPIEL JN. Acute Poststreptococcal Polymyalgia With Trismus. *Pediatrics*. 1987;80(6):953-954.
38. Harats N, Gur H, Rubinow A. Acute poststreptococcal polymyalgia. *Annals of the Rheumatic Diseases*. 1986;45(1):47-49.
39. Jansen TL, Janssen M, Macfarlane JD, de Jong AJ. Post-streptococcal reactive myalgia: a novel syndrome secondary to infection with group A or G streptococci. *Br J Rheumatol*. 1998;37(12):1343-8.
40. Venuta A, Ferrari P, Beverelli A, Bettelli F, Laudizi L. Acute post-streptococcal polymyalgia: two new cases with a review of the literature. *Eur J Pediatr*. 1995;154(6):475-6.
41. Alshaikh M, Kakakios AM, Kemp AS. Orbital myositis following streptococcal pharyngitis. *J Paediatr Child Health*. 2008;44(4):233-4.
42. Culligan B. Orbital myositis following streptococcal pharyngitis in a pediatric patient. *Optometry*. 2005;76(4):250-8.
43. Purcell JJ, Taulbee WA. Orbital myositis after upper respiratory tract infection. *Arch Ophthalmol*. 1981;99(3):437-8.
44. Nordstrand A, Norgren M, Holm SE. Pathogenic mechanism of acute post-streptococcal glomerulonephritis. *Scand J Infect Dis*. 1999;31(6):523-37.
45. Cu GA, Mezzano S, Bannan JD, Zabriskie JB. Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephritis. *Kidney Int*. 1998;54(3):819-826.
46. Berge A, Björck L. Streptococcal Cysteine Proteinase Releases Biologically Active Fragments of Streptococcal Surface Proteins. *Journal of Biological Chemistry*. 1995;270(17):9862-9867.
47. Kotb M. Bacterial pyrogenic exotoxins as superantigens. *Clin. Microbiol. Rev*. 1995;8(3):411-426.
48. Binks M, Sriprakash KS. Characterization of a Complement-Binding Protein, DRS, from Strains of *Streptococcus pyogenes* Containing the *emm12* and *emm55* Genes. *Infect. Immun*. 2004;72(7):3981-3986.
49. Fernie-King BA, Seilly DJ, Binks MJ, Sriprakash KS, Lachmann PJ. Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities. *Microbes and Infection*. 2007;9(3):300-307.
50. Dale RC. Post-streptococcal autoimmune disorders of the central nervous system. *Dev Med Child Neurol*. 2005;47(11):785-91.
51. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling

- in Sydenham chorea. *Nat Med.* 2003;9(7):914-20.
52. Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. *J Immunol.* 1993;151(5):2820-8.
53. Bronze MS, Courtney HS, Dale JB. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. *J Immunol.* 1992;148(3):888-93.
54. Cardoso F, Eduardo C, Silva AP, Mota CC. Chorea in fifty consecutive patients with rheumatic fever. *Mov Disord.* 1997;12(5):701-3.
55. Mercadante MT, Busatto GF, Lombroso PJ, et al. The psychiatric symptoms of rheumatic fever. *Am J Psychiatry.* 2000;157(12):2036-8.
56. Pavone P, Bianchini R, Parano E, et al. Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection. *Pediatr Neurol.* 2004;30(2):107-10.
57. Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies: tics and obsessive-compulsive symptoms. *J Dev Behav Pediatr.* 1994;15(6):421-5.
58. Snider LA, Swedo SE. Post-streptococcal autoimmune disorders of the central nervous system. *Curr Opin Neurol.* 2003;16(3):359-65.
59. Snider LA, Swedo SE. PANDAS: current status and directions for research. *Mol Psychiatry.* 2004;9(10):900-7.
60. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. *Am J Psychiatry.* 1998;155(2):264-71.
61. Leckman JF. Phenomenology of tics and natural history of tic disorders. *Brain Dev.* 2003;25 Suppl 1:S24-8.
62. Ben-Pazi H, Livne A, Shapira Y, Dale RC. Parkinsonian features after streptococcal pharyngitis. *J Pediatr.* 2003;143(2):267-9.
63. Dale RC, Heyman I, Surtees RA, et al. Dyskinesias and associated psychiatric disorders following streptococcal infections. *Arch Dis Child.* 2004;89(7):604-10.
64. Dale RC, Church AJ, Surtees RA, et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. *Brain.* 2004;127(Pt 1):21-33.
65. Asbahr FR, Negrao AB, Gentil V, et al. Obsessive-Compulsive and Related Symptoms in Children and Adolescents With Rheumatic Fever With and Without Chorea: A Prospective 6-Month Study. *Am J Psychiatry.* 1998;155(8):1122-1124.
66. Swedo S, Rapoport J, Cheslow D, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. *Am J Psychiatry.* 1989;146(2):246-249.
67. Vincent A. Encephalitis lethargica: part of a spectrum of post-streptococcal autoimmune diseases? *Brain.* 2004;127(Pt 1):2-3.
68. Ritt M, Campean V, Amann K, et al. Transient encephalopathy complicating poststreptococcal glomerulonephritis in an adult with diagnostic findings consistent with cerebral vasculitis. *Am J Kidney Dis.* 2006;48(3):489-94.
69. Dursun I, Gunduz Z, Poyrazoglu HM, et al. Cerebral vasculitis and unilateral sixth-nerve palsy in acute post-streptococcal glomerulonephritis. *Ann Trop Paediatr.* 2008;28(2):155-9.
70. Wong W, Morris MC. Cerebral vasculitis in a child following post-streptococcal glomerulonephritis. *J Paediatr Child Health.* 2001;37(6):597-9.
71. Reddy UP, Albini TA, Banta JT, Davis JL. Post-streptococcal vasculitis. *Ocul Immunol Inflamm.* 2008;16(1):35-6.
72. Dajani AS, Bisno AL, Chung KJ, et al. Prevention of rheumatic fever: a statement for health professionals by the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council on Cardiovascular Disease in the young, the American Heart Association. *Pediatr Infect Dis J.* 1989;8(5):263-6.
73. Murphy ML, Pichichero ME. Prospective Identification and Treatment of Children With Pediatric Autoimmune Neuropsychiatric Disorder Associated With Group A Streptococcal Infection (PANDAS). *Arch Pediatr Adolesc Med.* 2002;156(4):356-361.
74. Lisa AS, Lorraine L, Marcia S, Paul G, Susan ES. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. *Biological psychiatry.* 2005;57(7):788-792.
75. Ballinger S. Henoch-Schonlein purpura. *Curr Opin Rheumatol.* 2003;15(5):591-4.
76. Chang WL, Yang YH, Wang LC, Lin YT, Chiang BL. Renal manifestations in Henoch-Schonlein purpura: a 10-year clinical study. *Pediatr Nephrol.* 2005;20(9):1269-72.
77. Pillebout E, Thervet E, Hill G, et al. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. *J Am Soc Nephrol.* 2002;13(5):1271-8.
78. Davin J, Weening J. Diagnosis of Henoch-Schönlein purpura: renal or skin biopsy? *Pediatric Nephrology.* 2003;18(12):1201-1203.
79. al-Sheyyab M, Batiha A, el-Shanti H, Daoud A. Henoch-Schonlein purpura and streptococcal infection: a prospective case-control study. *Ann Trop Paediatr.* 1999;19(3):253-5.
80. Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N. Group A streptococcal antigen in the glomeruli of children with Henoch-Schonlein nephritis. *Am J Kidney Dis.* 2003;41(2):366-70.
81. Koskimies O, Mir S, Rapola J, Vilska J. Henoch-Schonlein nephritis: long-term prognosis of unselected patients. *Arch Dis Child.* 1981;56(6):482-4.
82. Bhullar N, Folzenlogen DD. Henoch-Schonlein purpura: upper respiratory tract infection or drug induced? *Arch Intern Med.* 2002;162(2):222-3.
83. David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. *Arch Dis Child.* 1993;69(6):685-8.
84. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics.* 2004;114(6):1708-33.
85. Wann ER, Fehringer AP, Ezepechuk YV, et al. Staphylococcus aureus isolates from patients with Kawasaki disease express high levels of protein A. *Infect Immun.* 1999;67(9):4737-43.
86. Matsubara K, Fukaya T, Miwa K, et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. *Clin Exp Immunol.* 2006;143(3):427-34.
87. Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. *Lancet.* 1993;342(8884):1385-8.
88. Gupta-Malhotra M, Viteri-Jackson A, Thomas W, Zabriskie JB. Antibodies to highly conserved peptide sequence of staphylococcal and streptococcal superantigens in Kawasaki disease. *Exp Mol Pathol.* 2004;76(2):117-21.
89. Floret D. [Clinical aspects of streptococcal and staphylococcal toxic diseases]. *Arch Pediatr.* 2001;8 Suppl 4:762s-768s.
90. Yoshioka T, Matsutani T, Toyosaki-Maeda T, et al. Relation of streptococcal pyrogenic exotoxin C as a causative superantigen for Kawasaki disease. *Pediatr Res.*

2003;53(3):403-10.

91. Hoare S, Abinun M, Cant AJ. Overlap between Kawasaki disease and group A streptococcal infection. *Pediatr Infect Dis J*. 1997;16(6):633-4.
92. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. *Expert Review of Anti-infective Therapy*. 2010;8(2):197-203.
93. Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. *Proc Natl Acad Sci U S A*. 1992;89(9):4066-70.
94. YOSHIOKA, MATSUTANI, IWAGAMI, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. *Immunology*. 1999;96(3):465-472.
95. Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. *Archives of Disease in Childhood*. 1995;72(4):308-311.
96. Gibson LE. Cutaneous vasculitis update. *Dermatol Clin*. 2001;19(4):603-15, vii.
97. Díaz-Pérez JL, De Lagrán ZM, Luis Díaz-Ramón J, Winkelmann RK. Cutaneous Polyarteritis Nodosa. *Seminars in Cutaneous Medicine and Surgery*. 2007;26(2):77-86.
98. Whittaker SJ, Dover JS, Greaves MW. Cutaneous polyarteritis nodosa associated with hepatitis B surface antigen. *J Am Acad Dermatol*. 1986;15(5 Pt 2):1142-5.
99. Sheth AP, Olson JC, Esterly NB. Cutaneous polyarteritis nodosa of childhood. *J Am Acad Dermatol*. 1994;31(4):561-6.
100. Ramos F, Figueira R, Fonseca JE, et al. [Juvenile cutaneous polyarteritis nodosa associated with streptococcal infection]. *Acta Reumatol Port*. 2006;31(1):83-8.
101. Kumar L, Thapa BR, Sarkar B, Walia BN. Benign cutaneous polyarteritis nodosa in children below 10 years of age--a clinical experience. *Ann Rheum Dis*. 1995;54(2):134-6.
102. Fisher I, Orkin M. CUTANEOUS FORM OF PERIARTERITIS NODOSA--AN ENTITY? *Arch Dermatol*. 1964;89:180-9.
103. Fathalla BM, Miller L, Brady S, Schaller JG. Cutaneous polyarteritis nodosa in children. *J Am Acad Dermatol*. 2005;53(4):724-8.
104. Albornoz MA, Benedetto AV, Korman M, et al. Relapsing cutaneous polyarteritis nodosa associated with streptococcal infections. *Int J Dermatol*. 1998;37(9):664-6.
105. Tonnelier JM, Ansart S, Tilly-Gentric A, Pennec YL. Juvenile relapsing periarteritis nodosa and streptococcal infection. *Joint Bone Spine*. 2000;67(4):346-8.
106. Leveque L, Turcu A, Bielefeld P, et al. [Adult cutaneous periarteritis nodosa and dental infections. Role of streptococci]. *Rev Med Interne*. 2001;22(10):992-6.
107. Geoffrey S, David W, Ivan R. Pustular vasculitis of the hands. *Journal of the American Academy of Dermatology*. 1995;32(2):192-198.
108. Yung A, Merchant W, Sheehan-Dare R. Streptococcus induced pustular vasculitis affecting the hands resembling pustular vasculitis of the hands--first reported case. *Clin Exp Dermatol*. 2005;30(4):366-8.
109. Katz SI, Gallin JI, Hertz KC, Fauci AS, Lawley TJ. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. *Medicine (Baltimore)*. 1977;56(5):443-55.
110. CREAM JJ, LEVENE GM, CALNAN CD. ERYTHEMA ELEVATUM DIUTINUM: AN UNUSUAL REACTION TO STREPTOCOCCAL ANTIGEN AND RESPONSE TO DAPSONE. *British Journal of Dermatology*. 1971;84(5):393-399.
111. Wilkinson SM, English JS, Smith NP, Wilson-Jones E, Winkelmann RK. Erythema elevatum diutinum: a clinicopathological study. *Clin Exp Dermatol*. 1992;17(2):87-93.
112. Auer-Grumbach P, Pfaffenthaler E, Soyer HP. Pustulosis acuta generalisata is a post-streptococcal disease and is distinct from acute generalized exanthematous pustulosis. *Br J Dermatol*. 1995;133(1):135-9.
113. Eren M, Fabri M, Krieg T, Eming SA. Pustulosis acuta generalisata with joint involvement in an HLA-A2- and HLA-B35-positive patient. *J Am Acad Dermatol*. 2008;58(6):1056-8.
114. Patrizi A, Savoia F, Giacomini F, Neri I, Ricci G. Diffuse acute pustular eruption after streptococcal infection--a new instance of pustulosis acuta generalisata. *Pediatr Dermatol*. 2007;24(3):272-6.
115. Moraes AJ, Soares PM, Zapata AL, et al. Panniculitis in childhood and adolescence. *Pediatr Int*. 2006;48(1):48-53.
116. Eberhard BA, Ilowite NT. Panniculitis and lipodystrophy. *Curr Opin Rheumatol*. 2002;14(5):566-70.
117. Schwartz RA, Nervi SJ. Erythema nodosum: a sign of systemic disease. *Am Fam Physician*. 2007;75(5):695-700.
118. Sanchez Yus E, Sanz Vico MD, de Diego V. Miescher's radial granuloma. A characteristic marker of erythema nodosum. *Am J Dermatopathol*. 1989;11(5):434-42.
119. Noah PW, Handorf CR, Skinner RB, Mandrell TD, Rosenberg EW. Skin basement membrane zone: a depository for circulating microbial antigen evoking psoriasis and autoimmunity. *Skinmed*. 2006;5(2):72-9; quiz 80-1.
120. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? *Clin Exp Immunol*. 1997;107 Suppl 1:21-4.
121. Gudjonsson JE, Thorarinnsson AM, Sigurgeirsson B, Kristinnsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. *Br J Dermatol*. 2003;149(3):530-4.
122. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. *Br J Dermatol*. 2001;145(6):886-90.
123. Nahary L, Tamarkin A, Kayam N, et al. An investigation of antistreptococcal antibody responses in guttate psoriasis. *Arch Dermatol Res*. 2008;(8).
124. Lewis HM, Baker BS, Bokth S, et al. Restricted T-cell receptor V beta gene usage in the skin of patients with guttate and chronic plaque psoriasis. *Br J Dermatol*. 1993;129(5):514-20.
125. Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. *The Journal of Clinical Investigation*. 1995;96(5):2106-2112.
126. Nyfors A, Rasmussen PA, Lemholt K, Eriksen B. Improvement of recalcitrant psoriasis vulgaris after tonsillectomy. *J Laryngol Otol*. 1976;90(8):789-94.
127. Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. *Clin Otolaryngol Allied Sci*. 1996;21(6):546-7.
128. Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. *J Dermatol*. 2000;27(8):508-12.
129. Wardrop P, Weller R, Marais J, Kavanagh G. Tonsillitis and chronic psoriasis. *Clin Otolaryngol Allied Sci*. 1998;23(1):67-8.
130. Dogan B, Karabudak O, Harmanyeri Y. Antistreptococcal treatment of guttate psoriasis: a controlled study. *Int J Dermatol*. 2008;47(9):950-2.

Author Information

Dedri M. Ivory, MD

University of Missouri Health Care

Darcy D. Folzenlogen, MD

University of Missouri Health Care